SWOT Analysis for Sunshine Biopharma Inc

30 Day SMA crossing over 200 Day SMA, and current price greater than open
Significant (over 30%) distance from 52 week high
Rising Net Cash Flow and Cash from Operating activity
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Company with Low Debt
Top Gainers
Stock with Low PE (PE < = 10)
Highest Recovery from 52 Week Low

Stocks with Quarter Change % less than Industry
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years
Highest fall from 52 Week High
Low Piotroski Score : Companies with weak financials
Book Value Per Share deteriorating for last 2 years
Weak Momentum: Price below Short, Medium and Long Term Averages
Recent Results: Declining Operating Profit Margin and Net Profits (YoY)
RSI indicating price weakness
Stocks Underperforming their Industry Price Change in the Quarter